

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jul 2026

### Evaluation of the effect of adding Atorvastatin to standard treatment in Helicobacter pylori eradication

#### Protocol summary

Eradication of Helicobacter pylori

##### Study aim

Considering the role of Helicobacter and the importance of eradication of this bacterium, we are finding a way to increase the success rate of Helicobacter pylori eradication compared to the existing standard treatment to reduce the complications of infection of this bacterium.

##### Design

A single-blind randomized clinical trial study The 120 patients will be divided into two groups of 60 in the control group (receiving standard treatment) and the intervention group (receiving Atorvastatin in addition to standard treatment) based on a random number table.

##### Settings and conduct

Outpatient Clinic of Imam Khomeini Hospital Patients are unaware of each other's treatment The control group receiving standard treatment, the other group added Atorvastatin to standard treatment, and after 4 weeks of treatment, all patients would undergo assess fecal Helicobacter pylori antigens

##### Participants/Inclusion and exclusion criteria

Age  $\geq$  18 years Absence of concurrent liver disease Absence of concurrent diabetes Not using statin in the past 6 months No history of gastric surgery No history of receiving H.pylori eradication therapy No antibiotics, PPI, H2 blockers, anti-inflammatory drugs and NSAIDs, bismuth salts in the past month No allergy to any of the antibiotics used in the study Absence of gastrointestinal malignancy No active gastrointestinal bleeding Non-pregnant and non-lactating No history of radiation therapy

##### Intervention groups

Standard treatment (a Bismuth Subcitrate 240 mg tablet, a Pantoprazole 40 mg tablet, a metronidazole 500mg tablet, and 2 amoxicillin 500mg capsules, all every 12 hours for 14 days) is prescribed for all patients and patients in the intervention group in addition to standard treatment with Atorvastatin 40mg daily for 14 days

##### Main outcome variables

#### General information

##### Reason for update

##### Acronym

AHBPE

##### IRCT registration information

IRCT registration number: **IRCT20190823044589N1**

Registration date: **2019-12-28, 1398/10/07**

Registration timing: **retrospective**

Last update: **2019-12-28, 1398/10/07**

Update count: **0**

##### Registration date

2019-12-28, 1398/10/07

##### Registrant information

##### Name

Parham Porteghali

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 44 3198 8002

##### Email address

parham.porteghali@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-04-21, 1398/02/01

##### Expected recruitment end date

2019-12-21, 1398/09/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

## Trial completion date

empty

## Scientific title

Evaluation of the effect of adding Atorvastatin to standard treatment in Helicobacter pylori eradication

## Public title

Effect of Atorvastatin in Helicobacter pylori eradication

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

18 years or older Indication for Helicobacter pylori eradication

### Exclusion criteria:

liver disease at the same time Diabetes at the same time Statin use in 6 months History of gastric surgery History of treatment for eradication of H. pylori Antibiotics, PPIs, histamine receptor blockers, anti-inflammatory and non-steroidal drugs, bismuth salts in the past month Allergy to any of the antibiotics used in the study Gastrointestinal malignancy Active gastrointestinal bleeding Pregnant and lactating History of radiation therapy

## Age

From **18 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Participant

## Sample size

Target sample size: **120**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomly based on random number table

## Blinding (investigator's opinion)

Single blinded

## Blinding description

Patients don't know medications other patients receive for treatment

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Urmia University of Medical

Sciences

#### Street address

West Azarbaijan University of Medical Sciences and Health services, next to emergency department, Jahad St., Resalat Boulevard

#### City

Urmia

#### Province

West Azarbaijan

#### Postal code

5714783734

#### Approval date

2019-07-31, 1398/05/09

#### Ethics committee reference number

IR.UMSU.REC.1398186

## Health conditions studied

### 1

#### Description of health condition studied

Helicobacter pylori infection

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

Helicobacter pylori eradication

#### Timepoint

After 4 weeks of completion of treatment

#### Method of measurement

38/5000 Evaluation of Helicobacter pylori fecal antigen

## Secondary outcomes

### 1

#### Description

Drug Side effects

#### Timepoint

During and after the course of treatment

#### Method of measurement

Ask the patient

## Intervention groups

### 1

#### Description

Intervention group: Atrostatin 40 mg at night for 14 days with standard treatment (including a Bismuth Subcitrate 240 mg tablet, a Pantoprazole 40 mg tablet, a metronidazole 500 mg tablet, and 2 x amoxicillin 500 mg capsules, all every 12 hours for 14 days)

#### Category

Treatment - Drugs

## 2

### Description

Control group: Standard treatment for 14 days (including a Bismuth Subcitrate 240 mg tablet, a Pantoprazole 40 mg tablet, a metronidazole 500 mg tablet, and 2 x amoxicillin 500 mg capsules, all every 12 hours for 14 days)

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Imam Khomeini Hospital

**Full name of responsible person**

Mohammad Reza Mohammad Hosseini Azar

**Street address**

Imam Khomeini Hospital, Ershad Street

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3346 9931

**Fax****Email**

emam-h-urm@umsu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Iraj Mohebbi

**Street address**

West Azarbaijan University of Medical Sciences and Health services, next to emergency department, Jihad St., Resalat Boulevard

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5714783734

**Phone**

+98 44 3223 4897

**Email**

mohebbi\_iraj@yahoo.co.uk

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Oroumia University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Mohammad Reza Mohammad Hosseini Azar

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

gastroenterology and hepatology

**Street address**

Imam Khomeini Hospital, Ershad Street

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3346 9931

**Email**

mohammadazar@gmail.com

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Mohammad Reza Mohammad Hosseini Azar

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

gastroenterology and hepatology

**Street address**

Imam Khomeini Hospital, Ershad Street

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3346 9931

**Email**

mohammadazar@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Parham Porteghali

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Imam Khomeini Hospital, Ershad Street

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3346 9931

**Email**

parham.porteghali@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All underlying information, grouping and the result of treatment of patients without mentioning the name of the patient in Excel and SPSS files are recorded and presented.

**When the data will become available and for how long**

6 months after the article to be published

**To whom data/document is available**

All academic and non-academic person

**Under which criteria data/document could be used**

In order to request the results and outputs of data analysis in the SPSS software, after submitting the application and approval of Urmia University of Medical Sciences, statistical outputs will be provided.

**From where data/document is obtainable**

Vice chancellor for research and technology of Urmia University of Medical Sciences

**What processes are involved for a request to access data/document**

After submitting the application and approval of the Deputy of research and Technology of Urmia University of Medical Sciences, the results will be sent during the maximum one month period by researcher.

**Comments**